(DOX) Amdocs - Overview
Stock: Software, Cloud, CRM, Monetization, Network
| Risk 5d forecast | |
|---|---|
| Volatility | 20.7% |
| Relative Tail Risk | -1.36% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.63 |
| Alpha | -24.69 |
| Character TTM | |
|---|---|
| Beta | 0.624 |
| Beta Downside | 0.696 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.80% |
| CAGR/Max DD | -0.28 |
EPS (Earnings per Share)
Revenue
Description: DOX Amdocs January 03, 2026
Amdocs Ltd (NASDAQ:DOX) supplies software and services to communications, entertainment, media, and other service providers worldwide, focusing on open, modular cloud offerings and AI-enhanced solutions.
Its flagship CES25 suite delivers a telco-native, GenAI-driven customer-experience platform that spans business, operations, and network domains, integrating AI tools for real-time personalization and automation.
Key product pillars include the Customer Engagement Platform (a telecom-specific CRM), the Monetization Suite for service pricing, the Intelligent Networking Suite for end-to-end orchestration, eSIM Cloud for digital SIM provisioning, MarketONE (a SaaS marketplace for digital services), and connectX-a “telco-in-a-box” cloud-native platform for digital operators.
Beyond software, Amdocs offers consulting, experience design, data and cloud services, network deployment and optimization, as well as managed services that incorporate predictive analytics, robotic process automation, and AI-driven quality engineering.
Financially, Amdocs reported FY 2023 revenue of approximately $4.9 billion, a 4 % YoY increase, with cloud-based services growing ~15 % YoY and operating margins around 10 %. The company’s exposure to 5G rollout and telecom operators’ shift toward digital transformation are primary growth drivers.
Sector-wide, global telecom capex is projected to rise 6 % in 2024, fueled by 5G expansion and increasing demand for AI-enabled BSS/OSS platforms-trends that directly benefit Amdocs’s product roadmap.
For a deeper quantitative assessment, you may find ValueRay’s platform useful for benchmarking Amdocs against peers and exploring valuation sensitivities.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 571.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 3.03 > 1.0 |
| NWC/Revenue: 1.81% < 20% (prev 4.56%; Δ -2.74% < -1%) |
| CFO/TA 0.14 > 3% & CFO 863.7m > Net Income 571.9m |
| Net Debt (704.5m) to EBITDA (950.6m): 0.74 < 3 |
| Current Ratio: 1.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (108.5m) vs 12m ago -4.34% < -2% |
| Gross Margin: 37.60% > 18% (prev 0.36%; Δ 3724 % > 0.5%) |
| Asset Turnover: 72.46% > 50% (prev 77.38%; Δ -4.91% > 0%) |
| Interest Coverage Ratio: 17.35 > 6 (EBITDA TTM 950.6m / Interest Expense TTM 43.3m) |
Altman Z'' 5.81
| A: 0.01 (Total Current Assets 1.54b - Total Current Liabilities 1.46b) / Total Assets 6.34b |
| B: 1.13 (Retained Earnings 7.16b / Total Assets 6.34b) |
| C: 0.12 (EBIT TTM 750.8m / Avg Total Assets 6.32b) |
| D: 1.19 (Book Value of Equity 3.42b / Total Liabilities 2.88b) |
| Altman-Z'' Score: 5.81 = AAA |
Beneish M -3.12
| DSRI: 1.03 (Receivables 962.8m/990.9m, Revenue 4.58b/4.87b) |
| GMI: 0.96 (GM 37.60% / 35.95%) |
| AQI: 1.01 (AQ_t 0.61 / AQ_t-1 0.60) |
| SGI: 0.94 (Revenue 4.58b / 4.87b) |
| TATA: -0.05 (NI 571.9m - CFO 863.7m) / TA 6.34b) |
| Beneish M-Score: -3.12 (Cap -4..+1) = AA |
What is the price of DOX shares?
Over the past week, the price has changed by -1.20%, over one month by -12.92%, over three months by -13.90% and over the past year by -12.64%.
Is DOX a buy, sell or hold?
- StrongBuy: 5
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the DOX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 95.5 | 30.6% |
| Analysts Target Price | 95.5 | 30.6% |
| ValueRay Target Price | 71.8 | -1.8% |
DOX Fundamental Data Overview February 08, 2026
P/E Forward = 9.4429
P/S = 1.7618
P/B = 2.2432
P/EG = 1.0496
Revenue TTM = 4.58b USD
EBIT TTM = 750.8m USD
EBITDA TTM = 950.6m USD
Long Term Debt = 647.1m USD (from longTermDebt, last quarter)
Short Term Debt = 167.8m USD (from shortTermDebt, last quarter)
Debt = 952.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 704.5m USD (from netDebt column, last quarter)
Enterprise Value = 8.77b USD (8.07b + Debt 952.4m - CCE 247.9m)
Interest Coverage Ratio = 17.35 (Ebit TTM 750.8m / Interest Expense TTM 43.3m)
EV/FCF = 11.62x (Enterprise Value 8.77b / FCF TTM 754.9m)
FCF Yield = 8.61% (FCF TTM 754.9m / Enterprise Value 8.77b)
FCF Margin = 16.49% (FCF TTM 754.9m / Revenue TTM 4.58b)
Net Margin = 12.49% (Net Income TTM 571.9m / Revenue TTM 4.58b)
Gross Margin = 37.60% ((Revenue TTM 4.58b - Cost of Revenue TTM 2.86b) / Revenue TTM)
Gross Margin QoQ = 37.04% (prev 37.38%)
Tobins Q-Ratio = 1.38 (Enterprise Value 8.77b / Total Assets 6.34b)
Interest Expense / Debt = 1.18% (Interest Expense 11.3m / Debt 952.4m)
Taxrate = 18.91% (37.0m / 195.4m)
NOPAT = 608.8m (EBIT 750.8m * (1 - 18.91%))
Current Ratio = 1.06 (Total Current Assets 1.54b / Total Current Liabilities 1.46b)
Debt / Equity = 0.28 (Debt 952.4m / totalStockholderEquity, last quarter 3.42b)
Debt / EBITDA = 0.74 (Net Debt 704.5m / EBITDA 950.6m)
Debt / FCF = 0.93 (Net Debt 704.5m / FCF TTM 754.9m)
Total Stockholder Equity = 3.45b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.05% (Net Income 571.9m / Total Assets 6.34b)
RoE = 16.56% (Net Income TTM 571.9m / Total Stockholder Equity 3.45b)
RoCE = 18.31% (EBIT 750.8m / Capital Employed (Equity 3.45b + L.T.Debt 647.1m))
RoIC = 14.73% (NOPAT 608.8m / Invested Capital 4.13b)
WACC = 7.44% (E(8.07b)/V(9.02b) * Re(8.21%) + D(952.4m)/V(9.02b) * Rd(1.18%) * (1-Tc(0.19)))
Discount Rate = 8.21% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.04%
[DCF Debug] Terminal Value 81.01% ; FCFF base≈676.3m ; Y1≈720.2m ; Y5≈864.5m
Fair Price DCF = 149.8 (EV 16.88b - Net Debt 704.5m = Equity 16.17b / Shares 107.9m; r=7.44% [WACC]; 5y FCF grow 7.21% → 2.90% )
EPS Correlation: 83.28 | EPS CAGR: 4.40% | SUE: -2.26 | # QB: 0
Revenue Correlation: -19.24 | Revenue CAGR: 0.25% | SUE: 0.40 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.76 | Chg30d=-0.040 | Revisions Net=-2 | Analysts=4
EPS current Year (2026-09-30): EPS=7.45 | Chg30d=+0.003 | Revisions Net=-3 | Growth EPS=+6.6% | Growth Revenue=+3.4%
EPS next Year (2027-09-30): EPS=8.10 | Chg30d=+0.032 | Revisions Net=+1 | Growth EPS=+8.8% | Growth Revenue=+3.4%